0000000000667259

AUTHOR

Susan M. Hall

showing 1 related works from this author

Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.

2011

Endothelin receptor antagonists are used to treat idiopathic pulmonary arterial hypertension (IPAH), but human pulmonary arterial endothelin receptor expression is not well defined. We hypothesised that disease and treatment would modify normal receptor distribution in pulmonary resistance arteries of children. Using immunohistochemistry and semiquantitative analysis, we investigated endothelin receptor subtypes A and B (ET(A) and ET(B), respectively), and endothelial nitric oxide synthase (eNOS) expression in peripheral pulmonary arteries of tissue from untreated children with IPAH (n=7), following extended combined bosentan and epoprostenol therapy (n=5) and from normal subjects (n=5). Cl…

Pulmonary and Respiratory MedicineMalePathologymedicine.medical_specialtyEndotheliumAdolescentNifedipineNitric Oxide Synthase Type IIIEndothelin A Receptor AntagonistsEndothelin B Receptor AntagonistsHypertension PulmonaryVasodilator AgentsPulmonary ArteryMuscle Smooth VascularPiperazinesSildenafil CitrateNitric oxidechemistry.chemical_compoundEnosInternal medicinemedicineHumansFamilial Primary Pulmonary HypertensionSulfonesReceptorChildAntihypertensive AgentsSulfonamidesbiologybusiness.industryBosentanbiology.organism_classificationReceptor Endothelin AEpoprostenolReceptor Endothelin BEndothelin A Receptor AntagonistsBosentanEndothelin B Receptor Antagonistsmedicine.anatomical_structureEndocrinologychemistryPurinesChild PreschoolDrug Therapy CombinationFemaleEndothelium VascularEndothelin receptorbusinessmedicine.drugThe European respiratory journal
researchProduct